Eye Disease & Ophthalmology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age

This Phase 3 trial is testing new digital therapies for children aged 8 to 12 with amblyopia, commonly known as lazy eye. The study compares two game-like treatments that use both eyes together against standard glasses correction. If these treatments work well, they could make therapy more enjoyable and easier for children, potentially leading to better vision improvements without invasive procedures.

Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

This study is looking at a similar digital therapy for younger children aged 4 to 7 using the Luminopia headset. It aims to determine if this new method matches the effectiveness of traditional patching but with a treatment that might be more engaging and less disruptive to daily life. Success in this study could provide a fresh option for early amblyopia care.

The EYERISING Study

This research is exploring whether repeated low-level red light therapy can slow the worsening of myopia, or nearsightedness, in children and young adults. Conducted in the United States and Nepal, the trial tests a simple, home-based approach that might help preserve eyesight and reduce the need for stronger glasses over time. Positive results could offer a practical new way to manage this common vision problem.

The Efficacy of a Polarized Folded Optical Path-based Reading-writing Desk for Myopia Prevention and Control in Pre-myopic Children

This trial evaluates a specially designed reading and writing desk meant to prevent or slow the development of myopia in children aged 5 to 10 who are at risk but do not yet have full myopia. If effective, this non-drug solution could provide families with an easy-to-use tool to protect children’s vision and reduce future eye health complications.

Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation

This study focuses on using adalimumab, a biologic medicine, to treat non-infectious uveitis, an eye inflammation that can cause serious damage if uncontrolled. The trial enrolls children in South Korea to assess if this treatment can safely reduce inflammation and improve outcomes. A successful trial could offer a valuable new treatment option for young patients with this condition.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.